Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/26460| Title: | Bortezomib for treatment-refractory autoimmune haemolytic anaemia following multivisceral transplantation. | Austin Authors: | Wong, Darren;Thomas, William;Butler, Andrew;Sharkey, Lisa | Affiliation: | Gastroenterology and Hepatology Department of Gastroenterology, Addenbrooke's Hospital, Cambridge, UK Department of Surgery, Addenbrooke's Hospital, Cambridge, UK Department of Haematology, Addenbrooke's Hospital, Cambridge, UK |
Issue Date: | 12-May-2021 | Date: | 2021 | Publication information: | BMJ Case Reports 2021; 14(5):e241634 | Abstract: | A 25-year-old man who received alemtuzumab as induction therapy for a multivisceral transplant experienced delayed onset of warm autoimmune haemolytic anaemia and neutropaenia. Serological testing and bone marrow biopsy excluded alternative causes. Haemolysis was refractory to standard therapies including corticosteroids, intravenous immunoglobulin and rituximab. The patient was successfully treated with bortezomib, a proteasome inhibitor, and has remained well as an outpatient without evidence of ongoing haemolysis. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/26460 | DOI: | 10.1136/bcr-2021-241634 | ORCID: | 0000-0003-1490-0547 | Journal: | BMJ Case Reports | PubMed URL: | 33980556 | Type: | Journal Article | Subjects: | GI bleeding haematology (drugs and medicines) transplantation |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.